Full View

Evaluation of dual versus triple therapy by landmark analysis in the RE-DUAL PCI trial

BE Peterson, DL Bhatt, P Gabriel Steg… - Cardiovascular …, 2021 - jacc.org
Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …
被引用次数：6 相关文章

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg, J Oldgren… - JACC: Cardiovascular …, 2021 - pure.au.dk
OBJECTIVES: The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg, J Oldgren… - JACC: Cardiovascular …, 2021 - vbn.aau.dk
OBJECTIVES: The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg… - Jacc …, 2021 - cris.maastrichtuniversity.nl
OBJECTIVES The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, P Gabriel Steg… - JACC: Cardiovascular …, 2021 - duo.uio.no
Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …
[PDF] academia.edu

[PDF][PDF] Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg, J Oldgren… - JACC …, 2021 - academia.edu
ABSTRACT OBJECTIVES The aim of this study was to explore the early versus late benefits
and risks of dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI …

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg, J Oldgren… - JACC: Cardiovascular …, 2021 - diva-portal.org
OBJECTIVES: The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.

BE Peterson, DL Bhatt, G Steg, J Oldgren… - JACC …, 2021 - europepmc.org
Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg, J Oldgren, M Maeng… - 2021 - pubmed.ncbi.nlm.nih.gov
Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …
[HTML] sciencedirect.com

[HTML][HTML] Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

BE Peterson, DL Bhatt, PG Steg, J Oldgren… - JACC: Cardiovascular …, 2021 - Elsevier
Objectives The aim of this study was to explore the early versus late benefits and risks of
dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized …